Latest Oncology News

Botensilimab/Balstilimab Combo Produces Deep Responses in Microsatellite Stable CRC

Botensilimab/Balstilimab Combo Produces Deep Responses in Microsatellite Stable CRC

June 29th 2022

Kristi Rosa

The combination of botensilimab and balstilimab elicited deep objective responses with evidence of durability and encouraging tolerability in heavily pretreated patients with microsatellite stable, metastatic colorectal cancer.

Atezolizumab Does Not Improve pCR in HER2-Positive Early Breast Cancer

Atezolizumab Does Not Improve pCR in HER2-Positive Early Breast Cancer

June 29th 2022

Jason Harris

Adding atezolizumab to neoadjuvant standard of care therapy for HER2-positive early breast cancer did not result in a better pathologic complete response compared with placebo, according to findings from the phase 3 IMpassion050 trial.

Second-Line RGX-202-01 Plus FOLFIRI/Bevacizumab Shows Early Efficacy, Safety in KRAS-Mutant CRC

Second-Line RGX-202-01 Plus FOLFIRI/Bevacizumab Shows Early Efficacy, Safety in KRAS-Mutant CRC

June 29th 2022

Kristi Rosa

A second-line combination regimen comprised of RGX-202-01, FOLFIRI and bevacizumab demonstrated an encouraging efficacy signal and a favorable toxicity profile in patients with KRAS-mutant colorectal cancer.

FDA Grants Breakthrough Therapy Designation to Talquetamab for Relapsed/Refractory Myeloma

FDA Grants Breakthrough Therapy Designation to Talquetamab for Relapsed/Refractory Myeloma

June 29th 2022

Kristi Rosa

The FDA has granted a breakthrough therapy designation to talquetamab for use as a potential therapeutic option in patients with relapsed or refractory multiple myeloma who received at least 4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody.

Socazolimab Shows Early Efficacy, Safety in Recurrent or Metastatic Cervical Cancer

Socazolimab Shows Early Efficacy, Safety in Recurrent or Metastatic Cervical Cancer

June 29th 2022

Chris Ryan

Socazolimab produced encouraging response rates with an acceptable safety profile in patients with recurrent or metastatic cervical cancer, irrespective of PD-L1 status, according to findings from the dose-expansion portion of a phase 1 trial.

Latest Oncology Videos

All Oncology News

Ixazomib/Daratumumab Elicits Encouraging Response in Elderly Frail Patients With R/R Multiple Myeloma

June 5th 2022

Ariana Pelosci

Ixazomib plus daratumumab without dexamethasone showed a positive efficacy profile for elderly frail patients with relapsed/refractory multiple myeloma, according to results of the phase 2 IFM 2018-02 study.

Panitumumab/mFOLFOX Establishes Prominent Role in RAS Wild-Type Metastatic CRC

June 5th 2022

Lisa Astor

The addition of panitumumab to mFOLFOX6 improved outcomes for patients with left-sided RAS wild-type metastatic colorectal cancer compared with bevacizumab and chemotherapy in the front-line setting, according to results from the phase 3 PARADIGM trial.

Lenvatinib Plus Pembrolizumab Improves PFS2 Outcomes in Advanced RCC

June 5th 2022

Brielle Benyon

Patients with advanced renal cell carcinoma who received lenvatinib plus pembrolizumab experienced a longer time to progression on next line of therapy compared with those who received sunitinib.

Trastuzumab Deruxtecan Is New Standard of Care for HER2-Low MBC

June 5th 2022

Silas Inman

Treatment with fam-trastuzumab deruxtecan-nxki doubled progression-free survival and reduced the risk of death by 36% compared with physician's choice of chemotherapy for patients with HER2-low, hormone receptor–positive metastatic breast cancer.

Daratumumab Plus RVd Demonstrates Durable MRD Negativity in Multiple Myeloma

June 5th 2022

Brielle Benyon

Daratumumab plus induction/consolidation lenalidomide, bortezomib, and dexamethasone elicited higher minimal residual disease-negativity rates vs the RVd combination alone in patients with transplant-eligible newly diagnosed multiple myeloma, including those in high-risk subgroups.

RVd Plus Transplant and Lenalidomide Maintenance Improves PFS in Newly Diagnosed Myeloma

June 5th 2022

Caroline Seymour

The combination of lenalidomide (Revlimid), bortezomib, and dexamethasone (RVd) plus autologous stem cell transplant as initial therapy followed by lenalidomide maintenance demonstrated a significant improvement in progression-free survival vs RVd alone followed by lenalidomide maintenance in patients with newly diagnosed multiple myeloma.

Biomarker Analysis Confirms Benefit of Alpelisib Plus Fulvestrant Regardless of Mutation Status in HR+/HER- Breast Cancer

June 5th 2022

Brittany Lovely

Alpelisib plus fulvestrant demonstrated a clinical benefit regardless of gene mutation status in patients with hormone receptor–positive, HER2-negative advanced breast cancer, including those with FGFR1 or FGFR2 alterations.

CT041 CAR T-cell Therapy Elicits Manageable Toxicity and Durable Response in Gastric/GEJ Cancer

June 5th 2022

Silas Inman

CT041, a Claudin18.2–specific CAR T-cell therapy, demonstrated a manageable safety profile in patients with previously treated, CLDN18.2-positive advanced gastric/gastroesophageal junction cancer, with a majority of patients achieving partial response or stable disease.

Lenvatinib Plus Pembrolizumab Bolsters PFS2 Outcomes in Advanced Endometrial Cancer

June 5th 2022

Tony Berberabe, MPH

The combination of lenvatinib and pembrolizumab demonstrated clinically meaningful improvements in progression-free survival on next line of therapy among all-comer patients with advanced endometrial cancer and those with DNA mismatch repair proficient disease, according to an exploratory analysis of the phase 3 KEYNOTE-775 trial.

Ribociclib Plus Switch Endocrine Therapy Elicits Benefit After CDK4/6 Progression in HR+/HER2– Metastatic Breast Cancer

June 5th 2022

Lisa Astor

Ribociclib plus endorcrine therapy led to a statistically significant improvement in progression-free survival in patients with hormone receptor–positive, HER2-negative unresectable or metastatic breast cancer with tumor progression following treatment with a CDK4/6 inhibitor, according to findings from the randomized phase 2 MAINTAIN trial.

Preview of ASCO 2022: Dr Everett Vokes

June 5th 2022

Caroline Seymour

OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Maintenance Avelumab Maintains Survival Benefit as First-Line Maintenance Across Subgroups in Advanced Urothelial Cancer

June 4th 2022

Benjamin Saylor

The addition of maintenance avelumab to best supportive care demonstrated improved outcomes for patients with advanced urothelial carcinoma including those who went on to receive second-line therapy.

TMB Serves as Predictive Biomarker of Toripalimab Efficacy in Urothelial Carcinoma

June 4th 2022

Jason Broderick

Tumor mutational burden served as a prognostic indicator of the efficacy of toripalimab among Chinese patients with urothelial carcinoma.

SOT101 Displays Antitumor Activity Alone and With Pembrolizumab in Advanced Solid Tumors

June 4th 2022

Caroline Seymour

SOT101 alone and in combination with pembrolizumab demonstrated a favorable safety profile with no additional toxicities reported and promising efficacy among patients with advanced solid tumors, according to findings from the phase 1 AURELIO-03 trial.

Palbociclib Plus Letrozole Misses OS End Point in ER+/HER2- Advanced Breast Cancer

June 4th 2022

Kyle Doherty

First-line treatment with palbociclib plus letrozole did not elicit a significant benefit in overall survival compared with letrozole monotherapy in patients with estrogen receptor-positive/HER2-negative advanced breast cancer missing the secondary end point of the trial.

See All News